GE HealthCare (Nasdaq: GEHC) announced today that it launched a new, all-in-one AI platform to support breast cancer detection.
The initial release of the GE HealthCare MyBreastAI Suite integrates three AI applications from iCad. That includes the ProFound AI for DBT, part of a platform that iCad today said demonstrates accurate breast cancer risk detection. It also integrates iCad’s SecondLook for 2D Mammography and PowerLook Density Assessment.
Chicago-based GE HealthCare says these apps support early detection, improve patient outcomes and enhance operational productivity.
ProFound AI for DBT provides information like lesion certainty of finding and case scores. These assist in prioritizing caseloads and clinical decision-making while reducing burnout.
SecondLook, a computer-aided detection (CAD) system, identifies and marks regions of interest on screening and diagnostic mammograms from GE HealthCare’s full-field digital mammography systems. It helps bring them to the attention of the radiologist after an initial reading’s completion.
PowerLook helps to standardize breast density assessment and reduce variability across multiple radiologists. It simplifies and standardizes reporting and stratification for clinicians while enabling accurate and reliable breast density assessments.
GE HealthCare cited studies showing that the deployment of these solutions assisted in prioritizing caseload and clinical decision-making. The company first plans to make the AI suite available in the U.S.
“As part of GE HealthCare’s ongoing commitment to transform healthcare and improve patient outcomes, we continue to explore how we can leverage the power of AI in mammography to support the early detection of breast cancer,” said Pooja Pathak, VP and GM of Mammography. “As screening guidelines continue to evolve and more attention is given to personal risk factors such as breast density, these kinds of tools are an important and exciting addition to our comprehensive portfolio of breast imaging technologies.”